Actively Recruiting

Age: 22Years +
All Genders
NCT06060041

IC-8 Apthera IOL New Enrollment Post Approval Study

Led by Bausch & Lomb Incorporated · Updated on 2026-01-12

435

Participants Needed

14

Research Sites

211 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The purpose of this study is to verify the post-market safety of the IC-8 Apthera IOL after the treatment of posterior capsular opacification (PCO), an expected complication related to IC-8 Apthera IOL implantation.

CONDITIONS

Official Title

IC-8 Apthera IOL New Enrollment Post Approval Study

Who Can Participate

Age: 22Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • 22 years of age or older, any race and any gender
  • Posterior capsule opacification (PCO) requiring treatment in the IC-8 Apthera IOL eye
  • Able to comprehend and have signed a statement of informed consent
  • Availability, willingness, ability and sufficient cognitive awareness to comply with examination procedures and study visits
  • Clear intraocular media in both eyes
  • Preoperative corneal astigmatism 641.5 D in the IC-8 Apthera IOL eye prior to IC-8 Apthera implantation
  • Prior IC-8 Apthera IOL implantation in one eye and a monofocal/monofocal toric IOL in the other eye per directions for use
Not Eligible

You will not qualify if you...

  • Pharmacologically dilated pupil size less than 7.0 mm in the IC-8 Apthera IOL eye
  • Irregular astigmatism in either eye
  • History of retinal disease
  • Active or recurrent anterior segment pathology
  • Presence of ocular abnormalities
  • Diagnosis of dry eye unable to maintain eye comfort or adequate vision despite treatment
  • Previous corneal or intraocular surgery except cataract surgery
  • History of ocular trauma or ocular conditions expected to require retinal laser or other surgery
  • Acute, chronic or uncontrolled systemic disease that may confound study outcomes
  • Patient is pregnant, plans pregnancy, lactating, or has hormone-related conditions causing refractive changes or dry eye
  • Current or recent participation in another clinical trial within 30 days
  • Plans to travel, relocate, or be unavailable for study visits

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 14 locations

1

Trinity Research Group, LLC

Dothan, Alabama, United States, 36301

Actively Recruiting

2

Feinerman Vision Center

Newport Beach, California, United States, 92663

Actively Recruiting

3

Argus Research Center

Cape Coral, Florida, United States, 33909

Actively Recruiting

4

Stephenson Eye Associates

Venice, Florida, United States, 34285

Actively Recruiting

5

Virdi Eye Clinic and Laser Vision Center

Rock Island, Illinois, United States, 61201

Actively Recruiting

6

Price Vision Group

Indianapolis, Indiana, United States, 46260

Actively Recruiting

7

Grene Vision Group

Wichita, Kansas, United States, 67206

Actively Recruiting

8

Oakland Eye

Birmingham, Michigan, United States, 48009

Actively Recruiting

9

Vance Thompson Vision - Omaha

Omaha, Nebraska, United States, 68137

Actively Recruiting

10

Eye Associates of New Jersey

Dover, New Jersey, United States, 07801

Actively Recruiting

11

Northern New Jersey Eye Institute

South Orange, New Jersey, United States, 07079

Actively Recruiting

12

Ophthalmic Partners, PC

Bala-Cynwyd, Pennsylvania, United States, 19004

Actively Recruiting

13

Berkeley Eye Center

Sugar Land, Texas, United States, 77478

Actively Recruiting

14

Utah Eye Centers

Bountiful, Utah, United States, 84010

Actively Recruiting

Loading map...

Research Team

J

Jennifer Laskowski

CONTACT

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here